SCHEMBL4014146

SCHEMBL4014146

Clc1ccc(Nc2cccc(-n3nc(Cl)c4ccccc43)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.41
ERBB3 P21860 1/20 0.41
SCN9A Q15858 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
MAPT P10636 7/20 0.38
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RAB9A P51151 2/20 0.38
ALPG P10696 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
AGPAT2 O15120 1/20 0.38
TP53 P04637 1/20 0.38
NPY5R Q15761 1/20 0.36
HPGD P15428 4/20 0.36
PDE5A O76074 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4015010 0.78 CCNT1 (0.46) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3571139 0.74 MAPT (0.54) EGFRERBB3CNR1CNR2MAPT
SCHEMBL16740282 0.71 BMI1 (0.50) MAPTKDM4ERAB9ATP53HPGD
SCHEMBL3577903 0.68 NOTUM (0.49) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3577056 0.67 CNR1 (0.45) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3578621 0.65 CNR1 (0.48) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3579788 0.65 SCN9A (0.42) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3574120 0.65 SCN9A (0.54) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL2891366 0.64 CDK2 (0.44) SCN9AMAPTKDM4EMEN1KMT2A
SCHEMBL4876232 0.64 RORC (0.46) SCN9AKDM4EKMT2AHPGDPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US claimed
CN-101516873-A Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH AS (DK) 2009-08-26 CN claimed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP claimed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO claimed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
CN-101516873-A Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH AS (DK) 2009-08-26 CN disclosed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP disclosed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS KCND2, KCNN3, KCNJ2 EGFR 4688/4885ERBB3 4137/4885SCN9A 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.